Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
3 Biotech Moonshots to Bet on the Future of Health
06:51pm, Monday, 06'th Nov 2023
Biotech stocks are incredibly risky but can provide investors with huge returns since insurers in the U.S. will pay tremendous amounts for successful treatments. In the last few months in particular,
Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
02:30pm, Tuesday, 31'st Oct 2023
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Exec
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
09:46am, Tuesday, 31'st Oct 2023
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.69 per share a year ago.
Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
03:44am, Wednesday, 11'th Oct 2023
Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult study showed that 63% of patients on crinecerfont
Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns
09:01am, Monday, 09'th Oct 2023
Here are four top-performing liquid stocks, Neurocrine Biosciences (NBIX), GigaCloud Technology (GCT), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for robust returns.
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
02:17pm, Tuesday, 03'rd Oct 2023
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
04:01pm, Thursday, 31'st Aug 2023
2023 Wells Fargo Healthcare Conference on September 7 in Boston Morgan Stanley 21st Annual Global Healthcare Conference on September 12 in New York SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Neurocrin
Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
06:01pm, Friday, 25'th Aug 2023
Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinecerfont, a treatment for congenital adrenal hyperpl
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatment
08:18am, Monday, 21'st Aug 2023
Neurocrine Biosciences Inc. NBIX, +2.55% said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder linked with Huntington's disease
Deerfield Management Company, L.P.
10:03pm, Tuesday, 01'st Aug 2023
Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
11:10am, Tuesday, 01'st Aug 2023
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Stree
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
11:38am, Tuesday, 25'th Jul 2023
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch
07:30pm, Monday, 24'th Apr 2023
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch.
3 Pharma Stocks That Could See a Surge in Demand in 2023
03:55pm, Monday, 24'th Apr 2023
As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticki
Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect
09:32am, Saturday, 22'nd Apr 2023
Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect.
